• Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; support of telehealth policies, including for audio-only telehealth services; H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R.3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 5860, the Continuing Appropriations Act, 2024 and Other Extensions Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024, and H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024 and H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024.
• Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024 and H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024.
• Funding for the HUD HOME program; H.R. 5860, the Continuing Appropriations Act, 2024 and Other Extensions Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024 and H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024.

Duration: November 1, 2007 to November 18, 2019

General Issues: Medicare/Medicaid, Health Issues, Budget/Appropriations, Pharmacy, Immigration, Disaster Planning/Emergencies, Economics/Economic Development, Homeland Security, Welfare, Urban Development/Municipalities, Education, Medical/Disease Research/Clinical Labs, Transportation, Insurance, Roads/Highway, Science/Technology, Defense

Spending: about $2,342,500 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2007: House of Representatives, U.S. Senate, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), U.S. Senate,, Administration on Aging, Y Y